Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH) in the United States. The company offers Cooled ThermoTherapy, which produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. It also provides Pr...
Urologix reported revenue of $14.24 million for fiscal year 2014, down 14.2% from fiscal year 2013, and net income of -$7.61 million. In Q3 2015 (the quarter ended March 31, 2015) revenue was $2.80 million, down 16.7% from a year before. Its market capitalization was $2,181 as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended June 30, 2014; market data as of October 8, 2026.
No profile data available.